Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
April 09, 2018 00:45 ET
|
NOVARTIS FINANCE S.A.
AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong...
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
March 27, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best...
NOVARTIS FINANCE S.A. : Directorate change
March 12, 2018 02:00 ET
|
NOVARTIS FINANCE S.A.
Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger...
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
February 01, 2018 16:05 ET
|
NOVARTIS FINANCE S.A.
Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase...
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
January 26, 2018 13:02 ET
|
NOVARTIS FINANCE S.A.
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera expands...
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
January 24, 2018 13:02 ET
|
NOVARTIS FINANCE S.A.
As filed with the US Securities and Exchange Commission on January 24, 2018 ...
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
January 24, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1...
Novartis appoints Elizabeth Barrett as Oncology Head
January 11, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development...
Novartis announces Oncology head to retire
December 15, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of...
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
November 13, 2017 12:00 ET
|
NOVARTIS FINANCE S.A.
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart...